Medexus Pharmaceuticals (MDP) Competitors

Medexus Pharmaceuticals (TSE:MDP) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Which has more risk and volatility, MDP or WEED?

Medexus Pharmaceuticals has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in MDP or WEED?

8.3% of Medexus Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of Canopy Growth shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has stronger earnings & valuation, MDP or WEED?

Medexus Pharmaceuticals has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$100.25M	0.68	C$3.26M	C$0.21	14.49
Canopy Growth	C$519.68M	0.54	-C$1.05B	-C$6.85	-0.26

Does the media refer more to MDP or WEED?

In the previous week, Medexus Pharmaceuticals had 5 more articles in the media than Canopy Growth. MarketBeat recorded 7 mentions for Medexus Pharmaceuticals and 2 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.21 beat Medexus Pharmaceuticals' score of -0.19 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medexus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Canopy Growth	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer MDP or WEED?

Medexus Pharmaceuticals presently has a consensus price target of C$5.49, indicating a potential upside of 81.11%. Canopy Growth has a consensus price target of C$2.20, indicating a potential upside of 25.71%. Given Medexus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Medexus Pharmaceuticals is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	4 Strong Buy rating(s)	3.29
Canopy Growth	3 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Is MDP or WEED more profitable?

Medexus Pharmaceuticals has a net margin of 3.25% compared to Canopy Growth's net margin of -201.27%. Medexus Pharmaceuticals' return on equity of 11.07% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	3.25%	11.07%	4.89%
Canopy Growth	-201.27%	-108.18%	-3.83%

Summary

Medexus Pharmaceuticals beats Canopy Growth on 14 of the 17 factors compared between the two stocks.